Head of Uro-Oncology Unit. @hospitalclinic. Chair of #eauguidelines Office uroweb.org/guidelines In love with Urology!! Passion for life!!!
Joined May 2014
- Tweets 15,671
- Following 2,349
- Followers 9,643
- Likes 21,985
864 Photos and videos
Maria J. Ribal retweeted
We see the tower of Jesus Christ illuminated for the first time!
The light show, starting from the base up to the illumination of the cross, culminated with a composition of lights guided by drones that traced the figure of Gaudí and the phrase “first love, then technique”.
855
7,997
44,413
3,947,438
Jun 5
Noordwijk @Uroweb week: Section Office, Scientific Congress Office, Patient Office Board, and National Societies.
A lot of behind-the-scenes work on collaboration, next year’s congress, and how we build standards, training, research and impact across Europe.
Good conversations, real alignment, and clear momentum.
This is how progress happens!! #eauguidelines
1
10
312
Maria J. Ribal retweeted
May 26
#ASCO26
Can we safely stop ADT ARPI in selected mHSPC patients after a deep response? 👀
The phase 2 A-DREAM trial suggests that some patients may enjoy prolonged treatment-free intervals with testosterone recovery after stopping therapy.
💡 Key findings from Abstract 5004:
▪️78 pts underwent treatment interruption
▪️58% remained treatment-free at 18 months
▪️41% remained treatment-free with testosterone recovery
▪️67% recovered eugonadal testosterone levels
▪️Median follow-up: 21.2 months
⚠️ Important caveats:
▪️Single-arm phase 2 study
▪️Highly selected exceptional responders
▪️No randomized comparator
▪️Long-term survival impact unknown
Still, this opens an important conversation around:
“Do all responders need indefinite continuous therapy?”
A major quality-of-life and survivorship question in modern prostate cancer care.
📖 Full abstract in comment ⬇️
#OncoTwitter #MedTwitter #ProstateCancer #mHSPC @ASCO @OncoAlert @UroToday @larvol
May 25
🧬 THE 10 MOST IMPORTANT GU CANCER TRIALS OF #ASCO26
🎯 PROSTATE CANCER: INTENSIFICATION vs QUALITY OF LIFE
1️⃣ PROTEUS
Perioperative apalutamide ADT in high-risk localized prostate cancer
Can aggressive ARPI intensification improve curative outcomes?
2️⃣ ARACOG (5005)
Darolutamide vs enzalutamide cognitive effects
One of the most important patient-centered prostate datasets of the meeting.
3️⃣ PEACE-3
Radium-223 enzalutamide in bone-metastatic mCRPC
Can alpha-emitter combinations improve survival meaningfully?
4️⃣ Mevrometostat Enzalutamide
Phase III EZH2 inhibition strategy in advanced prostate cancer
Targeting lineage plasticity and ARPI resistance.
BLADDER & UROTHELIAL CANCER: THE SEQUENCING ERA
5️⃣ KEYNOTE-B15 / EV-304
Perioperative EV pembrolizumab vs chemotherapy in MIBC
Could this finally replace cisplatin-based perioperative therapy?
6️⃣ IMvigor011
ctDNA-guided adjuvant atezolizumab in urothelial cancer
One of the definitive MRD/liquid biopsy trials at ASCO26.
7️⃣ POTOMAC (4624)
IO BCG in high-risk NMIBC
A major frontline positioning question.
8️⃣ EV-302 Long-Term Follow-Up (4507)
Extended outcomes for EV pembrolizumab in metastatic urothelial cancer
Long-term survival and toxicity data matter now.
RCC & PRECISION ADJUVANT THERAPY
9️⃣ LITESPARK-022
Adjuvant pembrolizumab belzutifan in high-risk ccRCC
Can HIF-2α inhibition improve adjuvant outcomes?
🔟 KEYNOTE-564 ctDNA Analysis
Who truly benefits from adjuvant pembrolizumab in RCC?
Potentially critical for avoiding overtreatment.
#GUOnc #OncTwitter #ASCO26 #ProstateCancer #BladderCancer #MedTwitter @ASCO @myesmo @esmo_open @Larvol
2
29
53
5,677
Maria J. Ribal retweeted
This was on one of my slides this year. In previous years I had spent countless hours toying with fonts, colors, placement, icons etc and AI has helped so much in streamlining the design side of slides and let me use my time for other more productive things.
2
1
6
531
Maria J. Ribal retweeted
May 25
Local salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients.
ja.ma/3PB2ojK
ALT Kaplan-Meier analysis of androgen deprivation therapy-free survival displays survival rates over 60 months for HDR-BT, sRP, SBRT, Cryotherapy, HIFU, and LDR-BT, with corresponding 'number at risk' data listed below the graph.
13
22
1,979
Maria J. Ribal retweeted
⏲️30 days to #CUA2026🍁We look forward to welcoming you to #Saskatoon for #CUA2026! Join us for outstanding presentations, valuable networking opportunities, and an exciting scientific program. View the full program and register today: cuameeting.org @MariaJRibal
1
5
6
584
Maria J. Ribal retweeted
May 21
⚡️ KEYNOTE-905 published in @NEJM: perioperative enfortumab vedotin pembrolizumab vs surgery alone in cisplatin-ineligible MIBC (n=344).
2-year EFS: 74.7% vs 39.4% (HR 0.40)
2-year OS: 79.7% vs 63.1% (HR 0.50)
pCR: 57.1% vs 8.6%
The trial that supported FDA approval in November 2025 — now with full data.
doi.org/10.1056/NEJMoa251167…
#BladderCancer
30
69
4,298
Maria J. Ribal retweeted
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).
Twittorial below
Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...
1/n
7
85
151
17,432
🔬 PEACE 2 phase III: Adding pelvic RT to prostate RT 3y ADT in very high-risk localized prostate cancer did NOT improve bPFS, MFS, CSS or OS. Borderline cPFS signal (HR 0.81, p=0.09). No added AEs. @PBlanchard_MD #ESTRO2026. @VedangMurthy what now?
6
60
137
10,289
Maria J. Ribal retweeted
May 16
ostate cancer screening is evolving fast.
📌 mpMRI remains the standard, reducing unnecessary biopsies by >70% and lowering detection of indolent cancers.
📌 bpMRI showed non-inferior detection vs mpMRI (PRIME trial) with faster, cheaper workflows.
📌 AI-assisted MRI reading (PI-CAI) achieved 50% fewer false positives.
📌 Emerging tools like microUS and PSMA PET/CT may further refine risk stratification and biopsy avoidance. #AUA26
9
47
3,506
Maria J. Ribal retweeted
#AUA26 Bayesian reanalysis of 8 phase III mHSPC trials presented by Dr. Yoshida:
🔴ARASENS, PEACE-1, ARANOTE, TITAN, ENZAMET, ARCHES, STAMPEDE, and LATITUDE
⚖️ Triplet therapy (ADT docetaxel ARPI) vs modern doublets
📉 No clear OS advantage overall → (HR 1.04)
🎲 Probability of ANY OS benefit: 36%
🎯 Probability of clinically meaningful benefit (HR<0.8): only 11%
Signal may exist in high-volume disease… but perhaps less than many expected.
@UroToday @AmericanUrological
1
23
61
5,604
Maria J. Ribal retweeted
BRCA1/2 may be telling us a bigger story.
A new ESMO Open study suggests that pathogenic BRCA1/2 variants may increase the risk of less common cancers beyond breast, ovarian, pancreatic, and prostate cancer.
Signals observed:
BRCA1 → thyroid cancer
BRCA2 → bladder, head & neck, and skin cancers
The most striking finding:
BRCA2-associated bladder cancer risk appeared particularly high in females.
These data are hypothesis-generating, but they may reshape how we think about hereditary cancer predisposition and precision oncology.
#BRCA #PrecisionOncology #CancerGenetics #Oncology
@ESMO_Open @OncoAlert
5
37
98
6,223
Maria J. Ribal retweeted
Our Special Issue in @UrolOncol continues with:
“Urethral Cancer Management in Contemporary Practice” — an updated review on the evolving multidisciplinary care of this rare malignancy.
An important contribution highlighting current evidence, ongoing challenges, and future directions in #UrethralCancer care.
Great job by @herneygarcia and @SpiessPhilippe on this important contribution to the field.
sciencedirect.com/science/ar…
@alirezaghoreifi @SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @CurtisPettaway1 @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @EauPatient @JadChahoud @benristau
6
12
1,364
Maria J. Ribal retweeted
This month in @actasurologicas elsevier.es/en-revista-actas…
We evaluated the reliability of NLP & Big Data (Savana®) in patients lo q-eisk
📊 Results were comparable to our institutional database, although expert validation remains essential.
#Urology #ProstateCancer #AI #NLP
1
2
7
705
Maria J. Ribal retweeted
El #ClínicObert 2026 apropa el Campus #Clínic a la ciutadania en una jornada que reuneix més de 6.000 persones
Gràcies a tots els que ho heu fet possible 🙌
ℹ️ clinicbarcelona.org/ca/notic…
1
12
35
1,830
Maria J. Ribal retweeted
🎊Èxit de la 2a edició del #ClínicObert! Una gran festa de la salut amb més de 100 activitats per compartir amb la ciutadania la feina de tot el #CampusCLÍNIC.
Gràcies a professionals, persones voluntàries, patrocinadors i assistents. Sense vosaltres no hagués estat possible! ❤️
1
10
51
2,880
May 9
Avui ha estat un dia molt especial @hospitalclinic #ClínicObert.
Hem pogut explicar al carrer el nostre projecte FIS/VIGIA de detecció precoç del #cancerbufeta: una recerca clínica dirigida a persones fumadores o exfumadores majors de 50, basada en l’anàlisi d’una mostra d’orina, sense radiació i sense proves invasives.
Durant tot el matí hem parlat amb persones que s’han apropat a la carpa, hem resolt dubtes i hem compartit una idea molt senzilla però molt important: en càncer de bufeta, detectar abans pot ajudar-nos a tractar millor.
Aquest tipus de jornades recorden per què fem recerca. No només per generar dades, sinó per transformar preguntes clíniques en oportunitats reals per als pacients.
Gràcies a tot l’equip de la Unitat d’Uro-oncologia, a @hospitalclinic, @idibaps i a totes les persones que avui han fet possible aquesta jornada.
#ClínicObert #CàncerDeBufeta #DeteccióPrecoç #RecercaClínica #UroOncologia #VIGIA #SomClínic
1
17
892
Maria J. Ribal retweeted
El #ClínicObert ja està en marxa! 🎉
✨Més de 100 activitats de salut, cuina, música, esport, xerrades i molt més!
🩺Apropar la salut, la ciència i la innovació a la ciutadania.
2
10
33
1,189